本帖最后由 老马 于 2012-1-13 21:20 编辑
; _9 z) v, ^$ a
9 o0 V, h! L$ b爱必妥和阿瓦斯丁的比较7 b7 m- m* i, a
' _8 ?/ \. L! B; Jhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
G" N2 i/ ]( S/ C" u/ o/ E
1 u8 `' B/ M2 k3 O4 |' O
. N) v. x; b' e) u- s9 zhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/3 `/ ?. h$ k( k2 b/ O0 V
==================================================
6 U: W; y3 T2 J% xOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)5 {, m# [ r0 h. s# D; J( o
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.3 w! B* \! W, g' t8 _
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.- G: D$ \8 W6 ?+ S! G5 q
|
11011102001537 )
显身卡
6 G8 I) m) K. w
